The association of metabolic syndrome and COVID-19 deterioration |
| |
| Institution: | 1. Department of Infectious Disease, AP-HP, Avicenne Hospital, Bobigny, France;2. Department of Endocrinology-Diabetology-Nutrition, AP-HP, Avicenne Hospital, Bobigny, France;3. Department of Internal Medicine, AP-HP, Avicenne Hospital, Bobigny, France;4. Department of Biology Laboratory, AP-HP, Avicenne Hospital, Bobigny, France;5. eXYSTAT, Malakoff, France;6. Department of Respiratory Disease, AP-HP, Avicenne Hospital, Bobigny, France;7. Department of Gastroenterology and Digestive Oncology, AP-HP, Avicenne Hospital, Bobigny, France;8. Equipe de Recherche en Epidémiologie Nutritionnelle (EREN), UMR U1153 Inserm / U1125 Inrae / Cnam / Université Paris 13 - Sorbonne Paris Nord, Centre de Recherche en Epidémiologie et Statistiques - Université de Paris (CRESS), SMBH PARIS 13, Bobigny, France;9. LEPS (Laboratoire Educations et Pratiques de Santé) EA 3412-Université Sorbonne Paris Nord, Bobigny, France;10. Laboratory for Vascular Translational Science (LVTS), Inserm U1148 Groupe Biothérapies et Glycoconjugués, Université Paris 13 – Sorbonne Paris Nord, France |
| |
| Abstract: | Background and aimsTo evaluate the prevalence and prognostic value of metabolic syndrome (MetS) in patients admitted for coronavirus disease 2019 (COVID-19).Methods and resultsIn this monocentric cohort retrospective study, we consecutively included all adult patients admitted to COVID-19 units between April 9 and May 29, 2020 and between February 1 and March 26, 2021. MetS was defined when at least three of the following components were met: android obesity, high HbA1c, hypertension, hypertriglyceridemia, and low HDL cholesterol. COVID-19 deterioration was defined as the need for nasal oxygen flow ≥6 L/min within 28 days after admission.We included 155 patients (55.5% men, mean age 61.7 years old, mean body mass index 29.8 kg/m2). Fifty-six patients (36.1%) had COVID-19 deterioration. MetS was present in 126 patients (81.3%) and was associated with COVID-19 deterioration (no-MetS vs MetS: 13.7% and 41.2%, respectively, p < 0.01). Logistic regression taking into account MetS, age, gender, ethnicity, period of inclusion, and Charlson Index showed that COVID-19 deterioration was 5.3 times more likely in MetS patients (95% confidence interval 1.3–20.2) than no-MetS patients.ConclusionsOver 81.3% of patients hospitalized in COVID-19 units had MetS. This syndrome appears to be an independent risk factor of COVID-19 deterioration. |
| |
| Keywords: | COVID-19 deterioration Metabolic syndrome Prevalence Prognosis BMI"} {"#name":"keyword" "$":{"id":"kwrd0035"} "$$":[{"#name":"text" "_":"Body mass index COVID-19"} {"#name":"keyword" "$":{"id":"kwrd0045"} "$$":[{"#name":"text" "_":"Coronavirus disease 2019 CRP"} {"#name":"keyword" "$":{"id":"kwrd0055"} "$$":[{"#name":"text" "_":"C-reactive protein ICU"} {"#name":"keyword" "$":{"id":"kwrd0065"} "$$":[{"#name":"text" "_":"Intensive care unit MetS"} {"#name":"keyword" "$":{"id":"kwrd0075"} "$$":[{"#name":"text" "_":"Metabolic syndrome Metabolic syndrome defined according to fasting glycemia instead of HbA1c PCR"} {"#name":"keyword" "$":{"id":"kwrd0095"} "$$":[{"#name":"text" "_":"Polymerase chain reaction |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
